ALKS vs INDV
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. INDV: A pharmaceutical company specialized in innovative treatments for substance use and mental health disorders.
Side-by-side fundamentals
| Metric | ALKS | INDV | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $52.73 | $40.03 | |
| Market cap as of 2026-08-04 | $8.8B | $4.9B | |
| P/E as of 2026-08-04 | 125.66 | 19.43 | INDV lower |
| PEG as of 2026-08-04 | -19.70 | 0.84 | ALKS lower |
| Net margin as of 2026-08-04 | +4.0% | +19.4% | INDV higher |
| Gross margin as of 2026-08-04 | +84.6% | +81.3% | ALKS higher |
| Operating margin as of 2026-08-04 | +7.0% | +24.4% | INDV higher |
| ROE as of 2026-08-04 | +3.7% | +159.1% | INDV higher |
| ROA as of 2026-08-04 | +2.0% | +19.1% | INDV higher |
| Debt / equity as of 2026-08-04 | 0.83 | 27.90 | ALKS lower |
| Revenue growth (YoY) as of 2026-08-04 | +10.8% | +10.3% | ALKS higher |
| Revenue CAGR (3y) SEC XBRL | +9.9% | +11.2% | INDV higher |
| Beta as of 2026-08-04 | 0.26 | 0.53 | |
| 1-year return as of 2026-07-27 close | +101.8% | +133.5% | INDV higher |
Fundamentals: market data, as of 2026-08-04. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.